全球基因治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

基因治療市場預計將從 2025 年的 85 億美元成長到 2034 年的 421.1 億美元，2026 年至 2034 年的複合年成長率為 19.45%。

受生物技術進步和人們對治療遺傳疾病日益成長的興趣的推動，全球基因治療市場正經歷顯著成長。基因治療是指透過修改或取代缺陷基因來治療或預防疾病，為過去被認為無法治癒的疾病提供了潛在的治療方法。研發投入的增加是推動市場擴張的主要動力。

關鍵促進因素包括遺傳疾病盛行率的不斷上升、對個人化醫療日益成長的需求以及CRISPR等基因編輯技術的進步。在有利的法規結構支持下，製藥和舉措正在積極開發創新治療方法。此外，合作關係和資金籌措正在加速臨床試驗和產品開發。

隨著新治療方法和改進型遞送系統的推出，預計未來市場將持續擴張。病毒載體和非病毒療法的進步將提升安全性和有效性。隨著科學研究的不斷深入，基因治療市場有望迎來變革性成長，並對全球醫療保健產生重大影響。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球基因治療市場：依適應症分類

• 市場分析、洞察與預測
• 大B細胞淋巴瘤
• 多發性骨髓瘤
• 脊髓性肌肉萎縮症（SMA）
• 急性淋巴性白血病（ALL）
• 惡性黑色素瘤（病變）
• 遺傳性視網膜疾病
• 重型BETA地中海貧血/鐮狀細胞疾病
• 其他

第5章 全球基因治療市場：依載體類型分類

• 市場分析、洞察與預測
• 慢病毒
• 逆轉錄病毒和γ逆轉錄病毒
• AAV
• 改良型單純皰疹病毒
• 腺病毒
• 其他

第6章：全球基因治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 靜脈
• 其他

第7章 全球基因治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen Inc
  • Novartis AG
  • F. Hoffmann-La Roche
  • Gilead Sciences Inc
  • Bluebird Bio Inc
  • Bristol-Myers Squibb Company
  • Legend Biotech
  • BioMarin
  • UniQure NV
  • Merck & Co
  • Sarepta Therapeutics Inc

The Gene Therapy Market size is expected to reach USD 42.11 Billion in 2034 from USD 8.50 Billion (2025) growing at a CAGR of 19.45% during 2026-2034.

The global gene therapy market is witnessing significant growth due to advancements in biotechnology and increasing focus on treating genetic disorders. Gene therapy involves modifying or replacing defective genes to treat or prevent diseases, offering potential cures for conditions that were previously considered untreatable. Rising investments in research and development are significantly driving market expansion.

Key drivers include increasing prevalence of genetic disorders, growing demand for personalized medicine, and advancements in gene editing technologies such as CRISPR. Pharmaceutical and biotechnology companies are actively developing innovative therapies, supported by favorable regulatory frameworks. Additionally, collaborations and funding initiatives are accelerating clinical trials and product development.

Looking ahead, the market is expected to expand with the introduction of new therapies and improved delivery systems. Advances in viral vectors and non-viral methods will enhance safety and effectiveness. As scientific research continues to progress, the gene therapy market is poised for transformative growth and significant impact on global healthcare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

• Large B-Cell Lymphoma
• Multiple Myeloma
• Spinal Muscular Atrophy (SMA)
• Acute Lymphoblastic Leukemia (ALL)
• Melanoma (lesions)
• Inherited Retinal Disease
• Beta-Thalassemia Major/SCD
• Others

By Vector Type

• Lentivirus
• RetroVirus & gamma RetroVirus
• AAV
• Modified Herpes Simplex Virus
• Adenovirus
• Others

By Route of Administration

• Intravenous
• Others

COMPANIES PROFILED

• Amgen Inc, Novartis AG, F HoffmannLa Roche, Gilead Sciences Inc, bluebird bio Inc, BristolMyers Squibb Company, Legend Biotech, BioMarin, uniQure NV, Merck Co, Sarepta Therapeutics Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENE THERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Large B-Cell Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Spinal Muscular Atrophy (SMA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Acute Lymphoblastic Leukemia (ALL) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Melanoma (lesions) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Inherited Retinal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Beta-Thalassemia Major/SCD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENE THERAPY MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Vector Type
• 5.2. Lentivirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. RetroVirus & gamma RetroVirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. AAV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Modified Herpes Simplex Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENE THERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENE THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Indication
  • 7.2.2 By Vector Type
  • 7.2.3 By Route Of Administration
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Indication
  • 7.3.2 By Vector Type
  • 7.3.3 By Route Of Administration
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Indication
  • 7.4.2 By Vector Type
  • 7.4.3 By Route Of Administration
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Indication
  • 7.5.2 By Vector Type
  • 7.5.3 By Route Of Administration
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Indication
  • 7.6.2 By Vector Type
  • 7.6.3 By Route Of Administration
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENE THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Amgen Inc
  • 9.2.2 Novartis AG
  • 9.2.3 F. Hoffmann-La Roche
  • 9.2.4 Gilead Sciences Inc
  • 9.2.5 Bluebird Bio Inc
  • 9.2.6 Bristol-Myers Squibb Company
  • 9.2.7 Legend Biotech
  • 9.2.8 BioMarin
  • 9.2.9 UniQure N.V
  • 9.2.10 Merck & Co
  • 9.2.11 Sarepta Therapeutics Inc